205 related articles for article (PubMed ID: 22459417)
1. Synovium CD20 expression is a potential new predictor of bone erosion progression in very-early arthritis treated by sequential DMARDs monotherapy -- a pilot study from the VErA cohort.
Lanfant-Weybel K; Michot C; Daveau R; Milliez PY; Auquit-Auckbur I; Fardellone P; Brazier M; Mejjad O; Daragon A; Krzanowska K; Jouen F; Tron F; Le Loarer F; Le Loët X; Vittecoq O
Joint Bone Spine; 2012 Dec; 79(6):574-80. PubMed ID: 22459417
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
3. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression.
Syversen SW; Goll GL; van der Heijde D; Landewé R; Gaarder PI; Odegård S; Haavardsholm EA; Kvien TK
J Rheumatol; 2009 Feb; 36(2):266-72. PubMed ID: 19132792
[TBL] [Abstract][Full Text] [Related]
4. Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis.
Meyer O; Nicaise-Roland P; Santos MD; Labarre C; Dougados M; Goupille P; Cantagrel A; Sibilia J; Combe B
Arthritis Res Ther; 2006; 8(2):R40. PubMed ID: 16469118
[TBL] [Abstract][Full Text] [Related]
5. Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade.
Rooney T; Edwards CK; Gogarty M; Greenan L; Veale DJ; FitzGerald O; Dayer JM; Bresnihan B
Rheumatol Int; 2010 Nov; 30(12):1571-80. PubMed ID: 19847430
[TBL] [Abstract][Full Text] [Related]
6. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.
Syversen SW; Gaarder PI; Goll GL; Ødegård S; Haavardsholm EA; Mowinckel P; van der Heijde D; Landewé R; Kvien TK
Ann Rheum Dis; 2008 Feb; 67(2):212-7. PubMed ID: 17526555
[TBL] [Abstract][Full Text] [Related]
7. Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate.
Hensvold AH; Joshua V; Li W; Larkin M; Qureshi F; Israelsson L; Padyukov L; Lundberg K; Defranoux N; Saevarsdottir S; Catrina AI
Arthritis Res Ther; 2015 Sep; 17(1):239. PubMed ID: 26337028
[TBL] [Abstract][Full Text] [Related]
8. Synovial Immunophenotype and Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiologic Prognosis.
Orr C; Najm A; Biniecka M; McGarry T; Ng CT; Young F; Fearon U; Veale DJ
Arthritis Rheumatol; 2017 Nov; 69(11):2114-2123. PubMed ID: 28732135
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for treatment change and radiographic progression in patients with rheumatoid arthritis in remission: a 5 year follow-up study.
Ramírez J; Cuervo A; Celis R; Ruiz-Esquide V; Castellanos-Moreira R; Narváez JA; Gómez-Puerta JA; Pablos JL; Sanmartí R; Cañete JD
Rheumatology (Oxford); 2021 Feb; 60(2):667-674. PubMed ID: 32653929
[TBL] [Abstract][Full Text] [Related]
10. Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis.
Zhang XP; Ma JD; Mo YQ; Jing J; Zheng DH; Chen LF; Wu T; Chen CT; Zhang Q; Zou YY; Lin JZ; Xu YH; Zou YW; Yang ZH; Ling L; Miossec P; Dai L
Front Immunol; 2021; 12():778480. PubMed ID: 34887865
[TBL] [Abstract][Full Text] [Related]
11. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA).
Hetland ML; Ejbjerg B; Hørslev-Petersen K; Jacobsen S; Vestergaard A; Jurik AG; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Skjødt H; Pedersen JK; Majgaard O; Svendsen AJ; Ellingsen T; Lindegaard H; Christensen AF; Vallø J; Torfing T; Narvestad E; Thomsen HS; Ostergaard M;
Ann Rheum Dis; 2009 Mar; 68(3):384-90. PubMed ID: 18388160
[TBL] [Abstract][Full Text] [Related]
12. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis.
Hammer HB; Ødegård S; Syversen SW; Landewé R; van der Heijde D; Uhlig T; Mowinckel P; Kvien TK
Ann Rheum Dis; 2010 Jan; 69(1):150-4. PubMed ID: 19095696
[TBL] [Abstract][Full Text] [Related]
13. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage.
Meyer O; Labarre C; Dougados M; Goupille P; Cantagrel A; Dubois A; Nicaise-Roland P; Sibilia J; Combe B
Ann Rheum Dis; 2003 Feb; 62(2):120-6. PubMed ID: 12525380
[TBL] [Abstract][Full Text] [Related]
14. Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: a simple model of prediction from a conservatively treated community-based inception cohort.
Le Loët X; Brazier M; Mejjad O; Boumier P; Daragon A; Gayet A; Pouplin S; Tron F; Zarnitsky C; Vittecoq O; Menard JF; Fardellone P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1739-47. PubMed ID: 20740612
[TBL] [Abstract][Full Text] [Related]
15. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis.
Boumans MJ; Thurlings RM; Yeo L; Scheel-Toellner D; Vos K; Gerlag DM; Tak PP
Ann Rheum Dis; 2012 Jan; 71(1):108-13. PubMed ID: 22072013
[TBL] [Abstract][Full Text] [Related]
16. Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study.
Benbouazza K; Benchekroun B; Rkain H; Amine B; Bzami F; Benbrahim L; Atouf O; Essakalli M; Abouqal R; Dougados M; Hajjaj-Hassouni N
BMC Musculoskelet Disord; 2011 Nov; 12():266. PubMed ID: 22111841
[TBL] [Abstract][Full Text] [Related]
17. Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies.
Takeuchi T; Soen S; Ishiguro N; Yamanaka H; Tanaka S; Kobayashi M; Okubo N; Nitta T; Tanaka Y
Mod Rheumatol; 2021 Jan; 31(1):34-41. PubMed ID: 31826682
[TBL] [Abstract][Full Text] [Related]
18. Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients.
Vittecoq O; Pouplin S; Krzanowska K; Jouen-Beades F; Menard JF; Gayet A; Daragon A; Tron F; Le Loet X
Rheumatology (Oxford); 2003 Aug; 42(8):939-46. PubMed ID: 12730503
[TBL] [Abstract][Full Text] [Related]
19. Prognostic laboratory markers of joint damage in rheumatoid arthritis.
Lindqvist E; Eberhardt K; Bendtzen K; Heinegård D; Saxne T
Ann Rheum Dis; 2005 Feb; 64(2):196-201. PubMed ID: 15458956
[TBL] [Abstract][Full Text] [Related]
20. Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression.
Ellingsen T; Hansen I; Thorsen J; Møller BK; Tarp U; Lottenburger T; Andersen LS; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Lindegaard H; Jacobsen S; Østergaard M; Vestergaard A; Jurik AG; Junker P; Christensen AF; Hetland ML; Hørslev-Petersen K; Stengaard-Pedersen K
Scand J Rheumatol; 2014; 43(2):91-100. PubMed ID: 23980529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
